Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone

F Sahr, R Ansumana, T A Massaquoi, B R Idriss, F R Sesay, J M Lamin, S Baker, S Nicol, B Conton, W Johnson, O T Abiri, O Kargbo, P Kamara, A Goba, J B W Russell, S M Gevao, F Sahr, R Ansumana, T A Massaquoi, B R Idriss, F R Sesay, J M Lamin, S Baker, S Nicol, B Conton, W Johnson, O T Abiri, O Kargbo, P Kamara, A Goba, J B W Russell, S M Gevao

Abstract

Background: Convalescent blood therapy has been a promising form of treatment for Ebola Virus Disease (EVD), but less attention has been focused on it for treatment.

Method: We assessed the effectiveness of convalescent whole blood (CWB) in the treatment of consented EVD patients. We recruited 69 subjects in December 2014 up to April 2015, at the 34 Military Hospital in Wilberforce and the PTS 1 Ebola Treatment Unit in Hastings, Freetown. Forty-four were given CWB, and 25 who consented but preferred to be exempted from the CWB treatment were used to compare clinical outcomes. All were given routine treatment used at the Ebola Treatment Unit.

Results: One of 44 subjects treated with CWB dropped out of the study and 31 recovered while 12 succumbed to the disease with a case fatality rate of 27.9%. For the group that was given routine treatment without CWB, 11 died with a case fatality rate of 44%. There was a significant difference between admission viral load and viral load after the first 24 h of treatment with convalescent whole blood (P < 0.01). The odds ratio for survival with CWB was 2.3 (95% CI, 0.8-6.5).

Conclusion: CWB is promising for treating EVD in resource-poor settings, especially in the early phases of outbreaks when resource-mobilization is done. Even though our sample size was small and the evaluation was not randomised, our results contribute to existing evidence that convalescent whole blood could be considered as a useful candidate for treating EVD. Further studies that are randomised will be required to further assess the efficacy of CWB as treatment option during any EVD outbreak.

Keywords: Convalescent whole blood; EVD; Sierra Leone; Treatment.

Copyright © 2016 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Figures

Figure 1
Figure 1
An example of EVD convalescent blood for transfusion.

References

    1. Edmond R.T., Evans B., Bowen E.T., Lloyd G. A case of Ebola virus infection. Br Med J. 1977;2(6086):541–544.
    1. Courtois D. Ebola virus three years later. Med Trop (Mars) 1979;39(6):675–684.
    1. Mupapa K., Massamba M., Kibadi K., Kuvula K., Bwaka A., Kipasa M. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis. 1999;179(Suppl. 1):S18–S23.
    1. Sadek R.F., Khan A.S., Stevens G., Peters C.J., Ksiazek T.G. Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival. J Infect Dis. 1999;179(Suppl. 1):S24–S27.
    1. Jahrling P.B., Geisbert J.B., Swearengen J.R., Larsen T., Geisbert T.W. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis. 2007;196(2):S400–S403.
    1. Parry R.P., Tettmar K.I., Hoschler K., Brailsford S.R., Samuel D., Ashford M. Strategies for screening blood donors to source convalesc ent H1N1v plasma for intervention therapy. Vox Sang. 2012;103(2):107–112.
    1. HUBER H.G. [Status of treatment with poliomyelitis convalescent serum] Kinderarztl Prax. 1953;21(7):311–314.
    1. Gundersen T. Convalescent blood for treatment of herpes zoster pphthalmicus: second report. Trans Am Ophthalmol Soc. 1940;38:124–137.
    1. Wong V.W.S., Dai D., Wu A.K.L., Sung J.J.Y. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J. 2003;9(3):199–201.
    1. Yeh K.M., Chiueh T.S., Siu L.K., Lin J.C., Chan P.K.S., Peng M.Y. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005;56(5):919–922.
    1. Mair-Jenkins J., Saavedra-Campos M., Baillie K., Cleary P., Khaw F.-M., Lim W.S. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral aetiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80–90.
    1. Hung I.F., To K.K., Lee C.K., Lee K.L., Chan K., Yan W.W. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52(4):447–456.
    1. van Griensven J., Edwards T., de Lamballerie X., Semple M.G., Gallian P., Baize S. Evaluation of convalescent plasma for Ebola Virus Disease in Guinea. N Engl J Med. 2016;374(1):33–42.
    1. van Griensven J., De Weiggheleire A., Delamou A., Smith P.G., Edwards T., Vandekerckhove P. The use of Ebola convalescent plasma to treat Ebola Virus Disease in resource-constrained settings: a perspective from the field. Clin Infect Dis. 2016;62(1):69–74.
    1. Burnouf T., Seghatchian J. Ebola virus convalescent blood products: where we are now and where we may need to go. Transfus Apher Sci. 2014;51(2):120–125.
    1. Thompson J.B., Mejabi P.F., Mejabi O.O., Tejan-Sie S.A. Convalescent serum therapy as rapid advance treatment for Ebola in West Africa. Int J African Dev. 2015;2(2):58–70.
    1. Campbell D.E., Georgiou G.M., Kemp A.S. Pooled human immunoglobulin inhibits IL-4 but not IFN-gamma or TNF-alpha secretion following in vitro stimulation of mononuclear cells with Staphylococcal superantigen. Cytokine. 1999;11(5):359–365.
    1. Qiu X., Wong G., Audet J., Bello A., Fernando L., Alimonti J.B. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514(7520):47–53.
    1. Marano G., Vaglio S., Pupella S., Facco G., Catalano L., Liumbruno G.M. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus. 2016;14:152–157.
    1. Organization World Health Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks. Interim Guid Natl Heal Authorities Blood Transfus Serv. 2014:1–19. WHO/HIS/SDS/2014.8.
    1. Ansumana R., Jacobsen K.H., Sahr F., Idris M., Bangura H., Boie-Jalloh M. Ebola in Freetown area, Sierra Leone–a case study of 581 patients. N Engl J Med. 2015;372(6):587–588.
    1. Fitzpatrick G., Vogt F., Moi Gbabai O.B., Decroo T., Keane M., De Clerck H. The contribution of Ebola viral load at admission and other patient characteristics to mortality in a Médecins Sans Frontières Ebola Case Management Centre, Kailahun, Sierra Leone, June–October 2014. J Infect Dis. 2015;212(10):1752–1758.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren